Consenso multidisciplinar sobre idoneidad farmacológica en cáncer de próstata hormono-sensible metastásico

Real-world prostate-specific antigen reduction and survival outcomes of metastatic hormone-sensitive prostate cancer patients treated with apalutamide: An observational, retrospective, and multicentre study.

“…It is worth noting that despite these indications, ADT monotherapy is still the treatment followed by several urologist, accounting for up to 56% of cases [ 21 ]. Importantly, apalutamide in combination with ADT presents a viable option for mHSPC patients all patients, except for the ones with a very bad basal status [ 22 ].…”